The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-19 and is reviewed periodically as new material appears.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
=== Computing === .MSI, the filename extension of Windows Installer packages Medium scale integration, a generation of integrated circuit chips which contain hundreds of transistors Message Signaled Interrupts, a PCI 2.2 interrupt-mechanism MSI protocol, a basic cache-coherence protocol used in multiprocessor systems
==== Canada ==== Taco Bell has been present in Canada since 1979, with the first store opening in Windsor, Ontario. There are currently Taco Bell locations in 8 of the 10 Canadian provinces: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick and Nova Scotia, Newfoundland and Labrador. Taco Bell had operated in the province of Quebec for close to 15 years, however announced its withdrawal on January 6, 2022. For some time it was possible to order draft beer with one's order. Taco Bell offers free soda refills in its stores. On March 31, 2011, Priszm, who was the largest franchisee for Taco Bell locations in Canada, went into bankruptcy protection in Ontario and British Columbia. On May 6, 2011, Priszm Income Fund was delisted from the Toronto Stock Exchange for failure to meet the continued listing requirements. Since then, some Taco Bell restaurants have been closed down including those in Guelph, Hamilton, and Cambridge, Ontario, among others.
The most important contribution to the science of controlled release include: (1) the development of polymers and copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) as drug carriers; (2) the introduction of enzymatically degradable derivatives of these polymers; (3) fundamental studies of the rates of enzymatic degradation of oligopeptide side-chains in polymers; (4) determination of the relationship between polymer structure and rates of pinocytic uptake of those polymers into cells; (5) design and preparation of polymers capable of specific intralysosomal release of chemically bound therapeutic agents; (6) fundamental studies of tissue localization of polymeric carriers bearing ligands for receptors expressed on the surfaces of specific target cells. Three HPMA copolymer - anticancer drug conjugates were in Phase I/II clinical trials.
An early-20th-century form of quackery was the treatment of maladies in a radiotorium. It was a small, sealed room for patients to be exposed to radon for its "medicinal effects". The carcinogenic nature of radon due to its ionizing radiation became apparent later. Radon's molecule-damaging radioactivity has been used to kill cancerous cells, but it does not increase the health of healthy cells. The ionizing radiation causes the formation of free radicals, which results in cell damage, causing increased rates of illness, including cancer. Exposure to radon has been suggested to mitigate autoimmune diseases such as arthritis in a process known as radiation hormesis. As a result, in the late 20th century and early 21st century, "health mines" established in Basin, Montana, attracted people seeking relief from health problems such as arthritis through limited exposure to radioactive mine water and radon. The practice is discouraged because of the well-documented ill effects of high doses of radiation on the body. Radioactive water baths have been applied since 1906 in Jáchymov, Czech Republic, but even before radon discovery they were used in Bad Gastein, Austria. Radium-rich springs are also used in traditional Japanese onsen in Misasa, Tottori Prefecture. Drinking therapy is applied in Bad Brambach, Germany, and during the early 20th century, water from springs with radon in them was bottled and sold (this water had little to no radon in it by the time it got to consumers due to radon's short half-life).
A month later, in May 1949, Thomas and his family moved to his final home, the Boat House at Laugharne, purchased for him at a cost of £2,500 in April 1949 by Margaret Taylor. Thomas acquired a garage a hundred yards from the house on a cliff ledge which he turned into his writing shed, and where he wrote several of his most acclaimed poems. He also rented "Pelican House" opposite his regular drinking den, Brown's Hotel, for his parents who lived there from 1949 until 1953.
Sources: en.wikipedia.org
== History == The company was founded in Bremen on 24 October 1923 as Bremer Flugzeugbau AG by Prof. Henrich Focke, Georg Wulf and Dr. rer. pol. Werner Naumann. Almost immediately, they renamed the company Focke-Wulf Flugzeugbau AG (later Focke-Wulf Flugzeugbau GmbH). Focke-Wulf merged, under government pressure, with Albatros Flugzeugwerke of Berlin in 1931. The Albatros Flugzeugwerke engineer and test pilot Kurt Tank became head of the technical department and started work on the Fw 44 Stieglitz (Goldfinch). Dr Ludwig Roselius became chairman in 1925 and handed over to his brother Friedrich in early 1933. In 1938 Roselius' HAG combine increased its shareholding to 46% and C. Lorenz AG secured 28%. The company was reconstituted as Focke-Wulf Flugzeugbau GmbH and no longer had to publish its accounts. A substantial capital injection occurred at this time. In August 1933 Hans Holle and Rudolf Schubert were given power of attorney over the Berlin branch of Focke-Wulf. Then in October 1933, Focke-Wulf Flugzeugbau A.G. Albatros Berlin was officially registered with the Department of Trade. Dr Roselius always remained the driving force of Focke-Wulf. He and his closest collaborator, Barbara Goette, often met with technical director Professor Kurt Tank. When Roselius died in May 1943, Heinrich Puvogel (later chair of Focke-Wulf) raised 4 million RM and continued handling the financial affairs of Focke-Wulf as chief of Seehandel A.G. Hanna Reitsch demonstrated the Focke-Wulf Fw 61, the first fully controllable helicopter (as opposed to autogyro), in Berlin in 1938.
== History == Safrole was obtained from a number of plants, but especially from the sassafras tree (Sassafras albidum), which is native to North America, and from Japanese star anise (Illicium anisatum, called shikimi in Japan). In 1844, the French chemist Édouard Saint-Èvre (1817–1879) determined safrole's empirical formula. In 1869, the French chemists Édouard Grimaux (1835–1900) and J. Ruotte investigated and named safrole. They observed its reaction with bromine, suggesting the presence of an allyl group. By 1884, the German chemist Theodor Poleck (1821–1906) suggested that safrole was a derivative of benzene, to which two oxygen atoms were joined as epoxides (cyclic ethers). In 1885, the Dutch chemist Johann Frederik Eijkman (1851–1915) investigated shikimol, the essential oil that is obtained from Japanese star anise, and he found that, upon oxidation, shikimol formed piperonylic acid, whose basic structure had been determined in 1871 by the German chemist Wilhelm Rudolph Fittig (1835–1910) and his student, the American chemist Ira Remsen (1846–1927). Thus, Eijkman inferred the correct basic structure for shikimol. He also noted that shikimol and safrole had the same empirical formula and had other similar properties, and thus he suggested that they were probably identical. In 1886, Poleck showed that upon oxidation, safrole also formed piperonylic acid, and thus shikimol and safrole were indeed identical. It remained to be determined whether the molecule's C3H5 group was a propenyl group (R−CH=CH−CH3) or an allyl group (R−CH2−CH=CH2).
Protein thermal stability is far from constant, however; for example, hyperthermophilic archaea have been found that grow at temperatures as high as 122 °C, which of course requires that their full complement of vital proteins and protein assemblies be stable at that temperature or above. The bacterium E. coli is the host for bacteriophage T4, and the phage encoded gp31 protein (P17313) appears to be structurally and functionally homologous to E. coli chaperone protein GroES and able to substitute for it in the assembly of bacteriophage T4 virus particles during infection. Like GroES, gp31 forms a stable complex with GroEL chaperonin that is absolutely necessary for the folding and assembly in vivo of the bacteriophage T4 major capsid protein gp23.
The first 7-Eleven store to open in Canada was in Calgary, Alberta, on June 29, 1969. There are 562 7-Eleven stores in Canada as of December 2022. Winnipeg, Manitoba, has the world's largest number of Slurpee consumers, with an estimated 1,500,000 Slurpees sold since the first 7-Eleven opened on March 21, 1970. All 7-Eleven locations in Canada are corporate operated. Like its U.S. counterparts every July 11 the stores offer free Slurpees on "7-Eleven Day". Many 7-Eleven locations offer petrol stations, either supplied by national distributors such as Imperial Oil and Petro-Canada, or under private label 7-Eleven branding. In March 2016, 7-Eleven acquired 148 Esso stations in Alberta and British Columbia from Imperial Oil for C$2.8 billion, with many of their convenience stores being converted to 7-Eleven. Some locations were not converted, and operate under the banner "smartstop 24/7" with their existing store formats, typically inherited from On the Run. In April 2025, 7-Eleven announced that it would convert its remaining 7-Eleven-branded petrol stations in Alberta and Ontario to either Esso, Mobil, or Petro-Canada. In November 2005, 7-Eleven started offering the Speak Out Wireless cellphone service in Canada. 7-Eleven locations also featured CIBC ATMs—in June 2012, these machines were replaced with ATMs operated by Scotiabank. 7-Eleven abandoned the Ottawa, Ontario, market in December 2009 after selling its six outlets to Quickie Convenience Stores, a regional chain.
== Further reading == Jenkins, Tiffany (2011). Contesting Human Remains in Museum Collections: the crisis of cultural authority. New York: Routledge. ISBN 9780415879606. Lohman, Jack; Goodnow, Katherine, eds. (2006). Human Remains & Museum Practice. Paris/London: UNESCO Publishing/Museum of London. ISBN 9789231040214. Graham, Shawn; Huffer, Damian (2020). "Reproducibility, Replicability, and Revisiting the Insta-Dead and the Human Remains Trade". Internet Archaeology (55). doi:10.11141/ia.55.11. The Bonetrade: Studying the online trade in human remains with machine learning and neural networks
Sources: en.wikipedia.org
=== Diabetes Mellitus === Increased levels of proinsulin in the circulatory system relative to mature insulin concentrations can indicate impending insulin resistance and the development of type 2 diabetes. Additional problems with proinsulin that can lead to diabetes include mutations in the number of cysteines present, which could affect correct folding. If the mutation causes only a mild change it could simply stress the endoplasmic reticulum’s ability to properly fold the protein. This stress, after a while, would lead to a decrease in the number of β-cells producing mature insulin, and would then lead to diabetes mellitus.
=== Procedure === During the insertion procedure, the provider will first insert a speculum into the vagina to get a good view of the cervix (the opening to the uterus). The provider will then cleanse the cervix. Next, the provider will hold the cervix and provide a gentle outward pull with a tool called a tenaculum, which stabilizes the cervix and straightens out entrance of the uterus (which is typically curved at rest). This increases ease of insertion and helps with proper placement of the IUD. A suction cervical stabilizer can be used in place of the standard tenaculum, and they may reduce pain associated with the insertion procedure. The next step of insertion is measurement of the depth of the uterine cavity with a thin uterine sounding (measuring) device. The provider will then set the measured uterine depth on the IUD insertion device to ensure proper placement. The IUD insertion device will then be inserted through the cervix into the uterus to place the IUD. The procedure itself, if uncomplicated, should take no more than five to ten minutes. For immediate postpartum insertion, the IUD is inserted following delivery of the placenta. After vaginal deliveries, insertions can be done using placental forceps, a longer inserter specialized for postpartum insertions, or manually. After cesarean deliveries, the IUD is placed in the uterus with forceps or manually during surgery before suturing the uterine incision. Generally, the removal is uncomplicated and reported to be not as painful as the insertion because no instrument is inserted through the cervix.
The first classification of birds was developed by Francis Willughby and John Ray in their 1676 volume Ornithologiae. Carl Linnaeus modified that work in 1758 to devise the taxonomic classification system currently in use. Birds are usually categorised as a biological class in traditional evolutionary taxonomy. Modern phylogenetic taxonomy places Aves in the clade Theropoda, sometimes with a Linnean rank lower than class, such as subclass or infraclass.
Molecular evidence of RNA editing in Bombyx chemosensory protein family. PLoS ONE 2014; 9: e86932. 10. Xuan N, Rajashekar B, Kasvandik S, Picimbon JF. Structural components of chemosensory protein mutations in the silkworm moth, Bombyx mori. Agri Gene 2016; 2: 53-58. 11. Xuan N, Rajashekar B, Picimbon JF. DNA and RNA-dependent polymerization in editing of Bombyx chemosensory protein (CSP) gene family. Agri Gene 2019; 12: 100087. 12. Picimbon JF. Mutations in the insect transcriptome. J Clin Exp Pathol. 2016; 6: 3. 13. Picimbon JF. A new view of genetic mutations. Australas Med J. 2017; 10: 701-715. 14. Picimbon JF. Evolution of protein physical structures in insect chemosensory systems. In: Picimbon JF (Ed.), Olfactory Concepts of Insect Control-Alternative to Insecticides. vol. 2 Springer Nature, Switzerland, 2019, pp. 231–263. 15. Campanacci V, Lartigue A, Hällberg BM, Jones TA, Giuici-Orticoni MT, Tegoni M, et al. Moth chemosensory protein exhibits drastic conformational changes and cooperativity on ligand binding. Proc Natl Acad Sci. USA 2003; 100: 5069-5074. 16. Picimbon JF, Dietrich K, Angeli S, Scaloni A, Krieger J, Breer H et al. Purification and molecular cloning of chemosensory proteins from Bombyx mori. Arch Insect Biochem Physiol. 2000b; 44: 120-129. 17. Picimbon JF, Dietrich K, Krieger J, Breer H. Identity and expression pattern of chemosensory proteins in Heliothis virescens (Lepidoptera, Noctuidae). Insect Biochem Mol Biol. 2001; 31: 1173-1181. 18. Wanner KW, Isman MB, Feng Q, Plettner E, Theilmann DA.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.